Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

It also seems to have a knack for filling those needs, as the apparent robust demand for Journavx indicates ... for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them.

It also seems to have a knack for filling those needs, as the apparent robust demand for Journavx indicates ... Pfizer, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Vertex Pharmaceuticals Incorporated (NASDAQ ... on diversifying its product portfolio and recently launched two new approved therapies: Alyftrek and Journavx. Alyfrtek is an improvement to VRTX’s CF ...

Casgevy and Journavx are poised to become significant growth drivers for Vertex Pharmaceuticals in the coming years, marking pivotal steps in the company's push to diversify its portfolio.

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).